BKV Infection, CMV Infection, EBV Infection
Conditions
Keywords
CMV, EBV, BKV, Multi-virus, CMV-associated diseases, EBV-associated diseases, BKV-associated diseases, Allogeneic Hematopoietic Stem Cell Transplantation, Virus-specific T cells, Infections, Virus Diseases, Antiviral-resistant infection, Anticancer therapy
Brief summary
The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after anticancer therapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). The main questions it aims to answer are: * What is the maximum tolerated dose of LB-DTK-MV based on dose-limiting toxicity? * Does the number of CMV, BKV, or EBV virus viral load decrease within 7 or 14 days after the second infusion of LB-DTK-MV? * Do treatment emergent adverse events occur after the second infusion? Participants will: * Receive a single intravenous infusion of LB-DTK-MV during the baseline visit (low dose: 1x10\^7/m\^2; high dose: 2x10\^7/m\^2). * Receive the second infusion of LB-DTK-MV intravenously at the same dose 14 days after the first infusion. * Attend weekly follow-up visits at the clinic for 6 months after the first dose.
Interventions
BIOLOGICALLB-DTK-MV
LB-DTK-MV is an allogeneic cell therapy product derived from a third-party donor and is supplied as a pale-yellow cell suspension at a final concentration of 4x10\^7cells/2mL in a colorless, transparent freeze-dried vial. The product is stored frozen until thawed into liquid before administration. Study participants will receive a single intravenous infusion of the assigned cell dose (low dose: 1x10\^7/m\^2;high dose: 2x10\^7/m\^2) of LB-DTK-MV on Visit 2 and 14 days after the initial dose.
Sponsors
LucasBio
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients aged 19 years or older who have undergone myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplantation using bone marrow, single or double umbilical cord blood, or peripheral blood stem cells (PBSCs). Or patients who have undergone any of the following anticancer treatments: * CAR-T: Kymriah, Yescarta * Bispecific Antibody: Glofitamab, Mosunetuzumab, Teclistamab, Elranatamab, etc 2. Patients diagnosed with single or multiple, antiviral-resistant CMV, BKV, and/or EBV despite receiving standard treatment. 3. Patients who are able to reduce their steroid dosage to 0.5mg/kg/day of Prednisolone (or an equivalent dose) or less. 4. Patients with a hemoglobin level ≥8.0g/dL. 5. Patients with evidence of neutrophil engraftment, defined as an absolute neutrophil count (ANC) maintained at 0.5x10\^3/μL or higher for 3 consecutive days following allogeneic hematopoietic stem cell transplantation. 6. Patients with peripheral oxygen saturation (SpO2) ≥90% on room air. 7. Patients who have at least one MHC class I HLA allele that matches the investigational product. 8. For women of childbearing potential, those who tested negative on a pregnancy test (blood test) performed on the screening visit. 9. Female subjects or male subjects with female partners who agree to use the following contraceptive methods during the duration of this clinical trial and who meet the following criteria: * Female participants or male participants with female partners who are postmenopausal (diagnosed with non-therapy-induced amenorrhea for 12 months or more or menopause) * Female subjects or the female partners of male subjects who are surgically sterile (i.e., lacking ovaries and/or a uterus) * Individuals who have agreed to strict abstinence during the clinical trial period \[For female participants, intermittent abstinence (e.g., withdrawal during ovulation, the basal body temperature method, or withdrawal after ovulation) does not constitute agreement to abstinence\] * If the female subject or the female partner of a male subject is a woman of childbearing potential (WOCBP) who has not undergone sterilization, those who meet the following criteria: * Hormonal contraceptives (implant, patch, oral) * Intrauterine devices * Dual barrier method (simultaneous use of the following two contraceptive methods: male condoms, female condoms, cervical caps, contraceptive diaphragms, contraceptive sponges) 10. Individuals who have voluntarily decided to participate in this clinical trial and have provided written consent to comply with the restrictions. 11. Individuals deemed suitable as trial subjects through screening tests (vital signs, physical examination, medical and surgical history, electrocardiogram, laboratory tests, etc.).
Exclusion criteria
1. Individuals who have received treatment with ATG (Antithymocyte Globulin), Campath (Alemtuzumab), or other T-cell immunosuppressive monoclonal antibodies within 28 days prior to the first dose. 2. Individuals who meet any of the following criteria at the time of screening: * Uncontrolled hypertension * Systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite taking antihypertensive medication. * Uncontrolled diabetes: Severe diabetes is defined as follows: * Severe hyperglycemia with HbA1C ≥ 10.0% * Individuals who have been hospitalized for diabetic ketoacidosis within the past 12 weeks. * Individuals who have received emergency treatment or been hospitalized within the past 12 weeks for severe hypoglycemia (glucose \<54 mg/dL) accompanied by seizures and loss of consciousness. * Other viral infections \[Ex. Human Immunodeficiency Virus(HIV), Hepatitis B Virus(HBV), Hepatitis C Virus(HCV)\]. However, patients who are tested negative for HBsAg and positive for anti-HBcAb are not subject to this exclusion criterion. * Tuberculosis * Syphilis * Moderate or severe liver damage \[Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \> 5 times the upper limit of normal (ULN)\] * Chronic kidney disease \[eGFR \< 30mL/min/1.73m\^2\] * Patients with other uncontrolled infections. However, the following cases are considered controlled infections and do not meet the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CMV viral load | From enrollment through 24 weeks after treatment initiation | CMV viral load testing is performed using RT-PCR on blood samples. Viral load is measured weekly for the first 4 weeks, followed by two measurements at 2-week intervals to monitor the progression of the infection, then once every 4 weeks, and subsequently once every 12 weeks. |
| BKV viral load | From enrollment through 24 weeks after treatment initiation. | BKV viral load testing is performed using RT-PCR on urine and blood samples. Viral load is measured weekly for the first 4 weeks, followed by two measurements at 2-week intervals to monitor the progression of the infection, then once every 4 weeks, and subsequently once every 12 weeks. |
| EBV viral load | From enrollment through 24 weeks after treatment initiation. | EBV load testing is performed using RT-PCR on blood samples. Viral load is measured weekly for the first 4 weeks, followed by two measurements at 2-week intervals to monitor the progression of the infection, then once every 4 weeks, and subsequently once every 12 weeks. |
| Immunogenicity Testing | From enrollment through 24 weeks after treatment initiation. | Immunogenicity testing using the IFN-γ ELISpot assay is performed weekly for the first 4 weeks following administration of the investigational drug. Thereafter, to evaluate the persistence and reconstitution of the immune response, measurements are taken twice at 2-week intervals, once at 4-week intervals, and once at 12-week intervals. Flow cytometry will be performed concurrently at each time point to evaluate cytokine profiles and immune cell subsets. |
| Adverse Events | From the baseline visit through 24 weeks after treatment initiation. | The investigator must confirm the occurrence of adverse events through medical examinations, including interviews and medical history reviews, during regular visits throughout the clinical trial period. Adverse events shall be assessed at each visit starting from the administration of the investigational drug at the baseline visit (Visit 2); however, from the baseline visit (Visit 2) until the discharge date, adverse events shall be assessed daily, and after the discharge date, assessments shall be conducted according to the procedures for each visit; diseases or symptoms that occurred prior to the first administration of the investigational drug shall be collected as part of the medical history. |
Countries
South Korea
Contacts
CONTACTNayoun Kim, Ph.D.
PRINCIPAL_INVESTIGATORDong-Gun Lee, MD-PhD
Department of Infectious Disease, The Catholic University of Korea Seoul St.Mary's Hospital
Outcome results
None listed